Premium
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Author(s) -
Garito Tania,
Roubenoff Ronenn,
Hompesch Marcus,
Morrow Linda,
Gomez Katherine,
Rooks Daniel,
Meyers Charles,
Buchsbaum Monte S.,
Neelakantham Srikanth,
Swan Therese,
Filosa Lee Anne,
Laurent Didier,
Petricoul Olivier,
Zakaria Marjorie
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13042
Subject(s) - insulin , insulin resistance , medicine , lean body mass , clamp , endocrinology , placebo , glucose clamp technique , insulin sensitivity , obesity , body mass index , pancreatic hormone , body weight , mechanical engineering , clamping , alternative medicine , pathology , engineering
Aim To test the hypothesis that an improving body composition in insulin‐resistant individuals could enhance insulin sensitivity. Methods A total of 16 people with a mean body mass index of 29.3 kg/m 2 and insulin resistance, received a single dose of bimagrumab or placebo and were assessed at week 10 for insulin sensitivity, using a hyperinsulinaemic‐euglycaemic clamp and an intravenous glucose tolerance test ( IVGTT ), and for body composition using dual energy X ‐ray absorptiometry and positron‐emission tomography. Results Bimagrumab increased lean mass by 2.7% ( P < .05) and reduced fat mass by 7.9% ( P = .011) at week 10 compared with placebo, and had a neutral effect on body weight. Bimagrumab reduced glycated haemoglobin by 0.21% at week 18 ( P < .001) and improved insulin sensitivity by ~20% (according to the clamp) to ~40% (according to the IVGTT ). Conclusion Taking the observed changes together, and given that these occurred without accompanying dietary intervention and without any prescribed regular physical exercise, bimagrumab may offer a novel approach for the treatment of the metabolic complications of obesity.